Choose VUMERITY® first

  • Strong efficacy for patients starting or switching therapy
  • Well-understood safety profile
  • Flexibility of a treatment that can go everywhere they go
Complete a Start Form today
  • The efficacy of VUMERITY is based upon bioavailability studies comparing dimethyl fumarate (DMF) to VUMERITY in patients with relapsing forms of MS and healthy subjects1
  • VUMERITY offers the established efficacy of DMF across Studies 1 and 2
  • In Study 1 and Study 2 pivotal trials, DMF demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1
  • Most common adverse reactions (incidence for DMF ≥10% and ≥2% more than placebo) were, respectively, flushing (40% and 6%), abdominal pain (18% and 10%), diarrhea (14% and 11%), and nausea (12% and 9%)

aBased on the number of MS prescriptions for the months May 2023 through October 2023 per IQVIA NPATM Monthly TRx data for all channels.

VUMERITY offers your patients:

Efficacy and safety outcomes
from switch patients

Switching to VUMERITY study

Well-established, real-world safety

Long-Term Study

Persistence and
refill adherence data

Real-World Study

Consistent support for
eligible patients

Coverage and Access